[
    [
        {
            "time": "",
            "original_text": "【迈瑞医疗】拟收购HyTest完善免疫诊断原料布局，IVD国际龙头未来可期【安信医药马帅团队】",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "HyTest",
                    "免疫诊断",
                    "IVD",
                    "国际龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "体外诊断"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【迈瑞医疗】拟收购HyTest完善免疫诊断原料布局，IVD国际龙头未来可期【安信医药马帅团队】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "央视新闻聚焦粤港澳大湾区 迈瑞医疗以自主创新提振湾区",
            "features": {
                "keywords": [
                    "央视新闻",
                    "粤港澳大湾区",
                    "迈瑞医疗",
                    "自主创新"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "区域经济"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "央视新闻聚焦粤港澳大湾区 迈瑞医疗以自主创新提振湾区",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "5月141家公司重要股东发布减持计划，中小市值股占比七成",
            "features": {
                "keywords": [
                    "减持计划",
                    "中小市值股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "市场整体"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "5月141家公司重要股东发布减持计划，中小市值股占比七成",
                "Correlation": 2,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "超40亿，知名药企被收购！",
            "features": {
                "keywords": [
                    "知名药企",
                    "收购",
                    "40亿"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "超40亿，知名药企被收购！",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "国元证券：迈瑞医疗（300760.SZ）携手HyTest，加强IVD原料研发和国际化布局，维持“买入”评级",
            "features": {
                "keywords": [
                    "国元证券",
                    "迈瑞医疗",
                    "HyTest",
                    "IVD",
                    "国际化布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "体外诊断"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国元证券：迈瑞医疗（300760.SZ）携手HyTest，加强IVD原料研发和国际化布局，维持“买入”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西南证券：迈瑞医疗（300760.SZ）收购Hytest切入IVD上游原料，维持“买入”评级",
            "features": {
                "keywords": [
                    "西南证券",
                    "迈瑞医疗",
                    "Hytest",
                    "IVD",
                    "上游原料"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "体外诊断"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "西南证券：迈瑞医疗（300760.SZ）收购Hytest切入IVD上游原料，维持“买入”评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西南证券维持迈瑞医疗买入评级：收购Hytest切入IVD上游原料，产业链布局助力再上新台阶",
            "features": {
                "keywords": [
                    "西南证券",
                    "迈瑞医疗",
                    "Hytest",
                    "IVD",
                    "产业链布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "体外诊断"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "西南证券维持迈瑞医疗买入评级：收购Hytest切入IVD上游原料，产业链布局助力再上新台阶",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "太平洋--迈瑞医疗：收购原料供应商Hytest，进口替代关键期重点攻克质量难关【公司研究】",
            "features": {
                "keywords": [
                    "太平洋证券",
                    "迈瑞医疗",
                    "Hytest",
                    "进口替代",
                    "质量难关"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "体外诊断"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "太平洋--迈瑞医疗：收购原料供应商Hytest，进口替代关键期重点攻克质量难关【公司研究】",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "20股获券商买入评级，春光科技目标涨幅达70.80%",
            "features": {
                "keywords": [
                    "券商买入评级",
                    "春光科技",
                    "目标涨幅"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "市场整体"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "20股获券商买入评级，春光科技目标涨幅达70.80%",
                "Correlation": 1,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "DEVINT | 迈瑞医疗斥资5.45亿欧元收购HyTest，推进体外诊断业务",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "HyTest",
                    "5.45亿欧元",
                    "体外诊断"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "体外诊断"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "DEVINT | 迈瑞医疗斥资5.45亿欧元收购HyTest，推进体外诊断业务",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]